Anakinra

證據等級: L5

預測適應症: 10 個

Anakinra: From Rheumatoid Arthritis to Extracutaneous Mastocytoma

One-Sentence Summary

Anakinra (Kineret) is a recombinant interleukin-1 receptor antagonist (IL-1Ra), established in clinical practice for rheumatoid arthritis and autoinflammatory conditions including Familial Mediterranean Fever and neonatal-onset multisystem inflammatory disease (NOMID). The TxGNN model ranks Extracutaneous Mastocytoma as its top novel indication with a prediction score of 99.93%; however, this prediction is supported by no clinical trials and no published literature, placing it at evidence level L5. Across the full top-10 predictions, the strongest clinically supported candidate is Autosomal Recessive Familial Mediterranean Fever (rank 3, L2 evidence, 20 publications), which carries substantially more actionable evidence and a direct mechanistic rationale.

Quick Overview

Item	Content
Original Indication	Rheumatoid arthritis; autoinflammatory conditions (no UK licence records retrieved — see note below)
Predicted New Indication	Extracutaneous Mastocytoma
TxGNN Prediction Score	99.93%
Evidence Level	L5
UK Market Status	No marketing authorisation on record
Number of Marketing Authorisations	0 (on record)
Recommended Decision	Hold

Note on UK market data: This evidence pack retrieved zero marketing authorisations for Anakinra in the UK. This almost certainly reflects a data collection gap rather than genuine absence of approval, as Kineret (anakinra) holds MHRA authorisation for rheumatoid arthritis and NOMID/CINCA. Clinicians should verify directly via the MHRA product licence register. A separate search against MHRA Public Assessment Reports is also recommended.

Why is This Prediction Reasonable?

Detailed mechanism of action data was not available in this evidence pack. Based on established clinical knowledge, anakinra is a recombinant, non-glycosylated form of the human IL-1 receptor antagonist (IL-1Ra) that competitively inhibits both IL-1α and IL-1β from binding to the interleukin-1 type I receptor (IL-1R1). By blocking this receptor, anakinra suppresses downstream NF-κB activation and the pro-inflammatory cytokine cascades that drive fever, joint destruction, serositis, and systemic autoinflammation.

Extracutaneous mastocytoma is a rare, benign mast cell proliferation occurring at extra-cutaneous sites, for which surgical excision remains the primary treatment. Mast cells do produce IL-1β and express IL-1 receptors, creating a theoretical topological connection within the TxGNN knowledge graph. However, the dominant pathological driver of mastocytoma — and of systemic mastocytosis more broadly — is an activating KIT mutation (D816V), which is entirely independent of the IL-1 signalling axis. There is currently no preclinical or clinical evidence that IL-1 blockade influences mast cell neoplasm growth or disease course. The high TxGNN prediction score most likely reflects an indirect graph-topology association between mast cells and IL-1, rather than a validated mechanistic pathway.

It is important for context that several other indications within the top-10 predictions carry considerably stronger mechanistic and clinical support. Autosomal Recessive Familial Mediterranean Fever (rank 3, L2) is driven by MEFV gene mutations that cause pyrin inflammasome over-activation and excessive IL-1β secretion — precisely the pathway that anakinra blocks. The AIRTRIP Phase 3 RCT (NCT02059291) has demonstrated efficacy in colchicine-resistant FMF, although this trial was not captured in the current data pull (a known database coverage gap). Pyogenic Autoinflammatory Syndrome (PAPA/PASH/PAPASH spectrum, rank 9, L3) similarly involves PSTPIP1-driven IL-1β overproduction, and a scoping review and multiple case series directly report anakinra efficacy in this population. These two indications represent considerably more clinically actionable repurposing opportunities than the top-ranked prediction.

Clinical Trial Evidence

Currently no related clinical trials registered.

Literature Evidence

Currently no related literature available.

UK Market Information

No marketing authorisation records for Anakinra were retrieved in this data pull. This is likely a data gap rather than a genuine absence of UK approval. Healthcare professionals should consult the following authoritative sources directly:

MHRA Product Licence Register: https://products.mhra.gov.uk/
BNF classification: Musculoskeletal diseases → Cytokine modulators (section 10.1.3)
NICE Technology Appraisal TA195: Anakinra for the treatment of rheumatoid arthritis (2009, guidance not recommended as routine use in RA; relevant for off-label NOMID/autoinflammatory indications)
Kineret SmPC: Available via the electronic medicines compendium (emc) at https://www.medicines.org.uk/emc

Based on publicly available information, Kineret is MHRA-authorised for: (1) rheumatoid arthritis in adults, in combination with methotrexate, in patients with inadequate response to DMARDs alone; and (2) neonatal-onset multisystem inflammatory disease (NOMID/CINCA). These records should be verified and retrieved to complete the evidence pack.

Safety Considerations

Please refer to the SmPC and BNF for safety information. Report suspected adverse reactions via the Yellow Card Scheme (https://yellowcard.mhra.gov.uk/).

Conclusion and Next Steps

Decision: Hold

Rationale: The TxGNN model’s top prediction for anakinra — extracutaneous mastocytoma — is grounded solely in knowledge graph topology, with no clinical trials, no supporting literature, and no established IL-1 mechanistic rationale specific to this rare benign mast cell tumour. This prediction cannot be meaningfully actioned at the current evidence level.

To proceed, the following is needed:

Preclinical evidence (in vitro or in vivo) demonstrating a functional, non-redundant role for IL-1 signalling in extracutaneous mastocytoma pathogenesis
MOA data retrieval from DrugBank (data gap DG002) to enable a structured mechanistic plausibility assessment
Correction of the UK marketing authorisation data gap — verify Kineret’s full MHRA licence status and retrieve approved indication text for the evidence pack
MHRA warnings and contraindications (data gap DG001) must be retrieved before any safety screening stage can be completed
Priority recommendation: Redirect investigative effort towards better-supported predictions — in particular, Autosomal Recessive FMF (rank 3, L2, Proceed with Guardrails) and Pyogenic Autoinflammatory Syndrome (rank 9, L3, Proceed with Guardrails) — both of which have strong mechanistic justification and existing clinical evidence; the FMF indication would benefit from retrieval of the AIRTRIP Phase 3 trial (NCT02059291) not captured in this data pull
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.